Literature DB >> 23816828

A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Mark Krauthamer1, Keren Rouvinov, Samuel Ariad, Sofia Man, Shlomo Walfish, Ilia Pinsk, Ignatio Sztarker, Tatiana Charkovsky, Konstantin Lavrenkov.   

Abstract

BACKGROUND: The ability of pretreatment laboratory markers of acute-phase inflammatory reactions like serum albumin level (SAL), hemoglobin (Hb), and absolute blood cell counts to predict complete pathological response (CPR) to neoadjuvant chemoradiotherapy (NACRT) in patients with locally advanced rectal cancer (LARC) has not yet been fully studied.
METHODS: We retrospectively examined the relation between SAL, Hb and absolute blood cell counts, and CPR rates in 140 LARC patients treated with NACRT.
RESULTS: Univariate analysis showed a significantly higher probability of CPR to NACRT in patients with clinical stage (CS) III LARC who had SAL >3.5 mg/dl (OR = 2.39; p = 0.04) and a neutrophil-to-lymphocyte ratio (NLR) value <5 (OR = 2.86; p = 0.03). The relation of CPR with SAL (OR = 2.11; p = 0.048) and NLR (OR = 2.54; p = 0.04) was confirmed by multivariate analysis in the same subset of patients. None of the parameters studied predicted CPR in patients with CS II disease. Patients who achieved CPR to NACRT had a higher probability of 5-year overall survival (HR 0.48; p = 0.01) and 5-year disease-free survival (HR 0.33; p = 0.003).
CONCLUSIONS: Our data indicate that SAL >3.5 mg/dl and NLR <5 may be positively related to CPR after NACRT in patients with CS III LARC. Hypoalbuminemia and a high NLR may be considered an indication for a more aggressive approach to NACRT and postoperative adjuvant chemotherapy in this subset of patients. This hypothesis requires confirmation in a randomized study.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23816828     DOI: 10.1159/000348385

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  25 in total

1.  Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Authors:  Ryuichiro Sawada; Takashi Akiyoshi; Yusuke Kitagawa; Yukiharu Hiyoshi; Toshiki Mukai; Toshiya Nagasaki; Tomohiro Yamaguchi; Tsuyoshi Konishi; Noriko Yamamoto; Masashi Ueno; Yosuke Fukunaga
Journal:  Ann Surg Oncol       Date:  2021-04-19       Impact factor: 5.344

Review 2.  Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.

Authors:  Lewis Stevens; Samir Pathak; Quentin M Nunes; Sanjay Pandanaboyana; Christian Macutkiewicz; Neil Smart; Andrew M Smith
Journal:  HPB (Oxford)       Date:  2014-11-27       Impact factor: 3.647

3.  Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.

Authors:  Hirokazu Kubo; Takashi Murakami; Ryusei Matsuyama; Yasuhiro Yabushita; Nobuhiro Tsuchiya; Yu Sawada; Yuki Homma; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

4.  Combining Radiomics and Blood Test Biomarkers to Predict the Response of Locally Advanced Rectal Cancer to Chemoradiation.

Authors:  Seung Hyuck Jeon; Changhoon Song; Eui Kyu Chie; Bohyoung Kim; Young Hoon Kim; Won Chang; Yoon Jin Lee; Joo-Hyun Chung; Jin Beom Chung; Keun-Wook Lee; Sung-Bum Kang; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

5.  Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.

Authors:  Lijun Shen; Hui Zhang; Liping Liang; Guichao Li; Ming Fan; Yongxin Wu; Ji Zhu; Zhen Zhang
Journal:  Radiat Oncol       Date:  2014-12-18       Impact factor: 3.481

6.  A Low Lymphocyte-to-Monocyte Ratio Predicts Unfavorable Prognosis in Pathological T3N0 Rectal Cancer Patients Following Total Mesorectal Excision.

Authors:  Wei-Wei Xiao; Lu-Ning Zhang; Kai-Yun You; Rong Huang; Xin Yu; Pei-Rong Ding; Yuan-Hong Gao
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

7.  Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer.

Authors:  Ik Yong Kim; Sei Hwan You; Young Wan Kim
Journal:  BMC Surg       Date:  2014-11-18       Impact factor: 2.102

8.  Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience.

Authors:  Euncheol Choi; Jin Hee Kim; Ok Bae Kim; Mi Young Kim; Young Ki Oh; Sung Gyu Baek
Journal:  Radiat Oncol J       Date:  2016-06-17

9.  Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.

Authors:  Katsuji Tokuhara; Yosuke Ueyama; Kazuyoshi Nakatani; Kazuhiko Yoshioka; Masanori Kon
Journal:  World J Surg Oncol       Date:  2016-04-30       Impact factor: 2.754

10.  Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer.

Authors:  Danielle S Bitterman; Lucas Resende Salgado; Harvey G Moore; Nicholas J Sanfilippo; Ping Gu; Ioannis Hatzaras; Kevin L Du
Journal:  Front Oncol       Date:  2015-12-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.